DE60238671D1 - Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium - Google Patents
Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von deliriumInfo
- Publication number
- DE60238671D1 DE60238671D1 DE60238671T DE60238671T DE60238671D1 DE 60238671 D1 DE60238671 D1 DE 60238671D1 DE 60238671 T DE60238671 T DE 60238671T DE 60238671 T DE60238671 T DE 60238671T DE 60238671 D1 DE60238671 D1 DE 60238671D1
- Authority
- DE
- Germany
- Prior art keywords
- glucocorticoid receptor
- delirium
- treatment
- receptor antagonist
- specific antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010012218 Delirium Diseases 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28861901P | 2001-05-04 | 2001-05-04 | |
| US13780002A | 2002-05-01 | 2002-05-01 | |
| PCT/US2002/014318 WO2002096433A1 (en) | 2001-05-04 | 2002-05-06 | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60238671D1 true DE60238671D1 (de) | 2011-02-03 |
Family
ID=26835589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60238671T Expired - Lifetime DE60238671D1 (de) | 2001-05-04 | 2002-05-06 | Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1390037B1 (enExample) |
| JP (2) | JP2005512949A (enExample) |
| CN (1) | CN1527713A (enExample) |
| AT (1) | ATE492281T1 (enExample) |
| AU (1) | AU2002303652B2 (enExample) |
| CA (1) | CA2446506C (enExample) |
| DE (1) | DE60238671D1 (enExample) |
| IL (2) | IL158744A0 (enExample) |
| NO (1) | NO334736B1 (enExample) |
| NZ (1) | NZ529456A (enExample) |
| WO (1) | WO2002096433A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2463446C (en) * | 2001-10-26 | 2010-02-23 | Akzo Nobel N.V. | Use of (11.beta., 17.beta.)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| CN103930027B (zh) * | 2011-10-07 | 2016-03-02 | 皇家飞利浦有限公司 | 用于监测患者并检测该患者的谵妄的监测系统 |
| CN116168840B (zh) * | 2023-04-23 | 2023-12-22 | 北京大学人民医院 | 一种预测术后谵妄发生风险的方法、设备及系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| IL110309A0 (en) * | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| CN1528315A (zh) * | 1997-10-06 | 2004-09-15 | ������˹̹�������ѧ�й�ίԱ�� | 治疗糖皮质素功能失调相关性精神病的方法 |
| CN1130200C (zh) * | 1998-05-15 | 2003-12-10 | 利兰·斯坦福青年大学托管委员会 | 用于治疗痴呆的糖皮质激素受体拮抗剂 |
| CN1556709A (zh) * | 2001-03-23 | 2004-12-22 | �Ƹ��� | 使用糖皮质激素受体特效拮抗剂治疗压力症的方法 |
-
2002
- 2002-05-06 IL IL15874402A patent/IL158744A0/xx unknown
- 2002-05-06 JP JP2002592943A patent/JP2005512949A/ja active Pending
- 2002-05-06 CN CNA028126726A patent/CN1527713A/zh active Pending
- 2002-05-06 NZ NZ529456A patent/NZ529456A/en not_active IP Right Cessation
- 2002-05-06 AT AT02731689T patent/ATE492281T1/de active
- 2002-05-06 EP EP02731689A patent/EP1390037B1/en not_active Expired - Lifetime
- 2002-05-06 DE DE60238671T patent/DE60238671D1/de not_active Expired - Lifetime
- 2002-05-06 WO PCT/US2002/014318 patent/WO2002096433A1/en not_active Ceased
- 2002-05-06 CA CA2446506A patent/CA2446506C/en not_active Expired - Fee Related
- 2002-05-06 AU AU2002303652A patent/AU2002303652B2/en not_active Ceased
-
2003
- 2003-11-04 IL IL158744A patent/IL158744A/en not_active IP Right Cessation
- 2003-11-04 NO NO20034916A patent/NO334736B1/no not_active IP Right Cessation
-
2008
- 2008-12-09 JP JP2008313766A patent/JP2009102346A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005512949A (ja) | 2005-05-12 |
| AU2002303652B2 (en) | 2006-08-31 |
| CA2446506C (en) | 2012-04-10 |
| NO20034916D0 (no) | 2003-11-04 |
| NZ529456A (en) | 2005-10-28 |
| EP1390037A4 (en) | 2005-03-30 |
| IL158744A (en) | 2011-11-30 |
| NO20034916L (no) | 2004-01-05 |
| CA2446506A1 (en) | 2002-12-05 |
| EP1390037B1 (en) | 2010-12-22 |
| WO2002096433A9 (en) | 2003-02-06 |
| IL158744A0 (en) | 2004-05-12 |
| NO334736B1 (no) | 2014-05-19 |
| JP2009102346A (ja) | 2009-05-14 |
| HK1059036A1 (en) | 2004-06-18 |
| ATE492281T1 (de) | 2011-01-15 |
| EP1390037A1 (en) | 2004-02-25 |
| WO2002096433A1 (en) | 2002-12-05 |
| CN1527713A (zh) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE317699T1 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
| ATE406166T1 (de) | Verfahren zur prävention von gewichtszunahme infolge von antipsychotika | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| EP1156792A4 (en) | METHOD AND COMPOSITION FOR TREATING IRRITABLE COLON SYNDROME WITH LOW DOSES OF OPIOID RECEPTOR ANTAGONISTS | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| ATE539768T1 (de) | Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen | |
| DE60234616D1 (de) | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| ATE447570T1 (de) | Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| ATE529116T1 (de) | Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect) | |
| DE60229411D1 (de) | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom | |
| MX2007004306A (es) | Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados. | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| ATE317268T1 (de) | Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis | |
| DE60238671D1 (de) | Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium | |
| MX2007003545A (es) | Composiciones y metodos para tratar trastornos cognitivos. | |
| ATE393766T1 (de) | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen | |
| DE60006948D1 (de) | Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten | |
| ATE396996T1 (de) | Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen |